Mold Toxicity Treatment: Binders, Protocols, and Recovery Timeline

Why Treatment Follows a Specific Sequence

Mold illness (CIRS) involves a self-reinforcing inflammatory loop. Biotoxins trigger innate immune activation, which produces inflammatory cytokines, which impair the body’s ability to clear the biotoxins, which sustains the immune activation. Breaking this loop requires a stepwise approach [1].

Random interventions don’t work well because each step depends on the previous one being completed. Starting binders before leaving the moldy environment means you’re constantly adding new biotoxins while trying to remove old ones. Starting VIP nasal spray before correcting MARCoNS means the treatment will fail because the nasal biofilm blocks VIP receptors.

The most widely used and best-documented treatment framework is the Shoemaker Protocol, developed by Dr. Ritchie Shoemaker based on published research and clinical outcomes from thousands of patients.

Step 1: Remove the Source

This is nonnegotiable. No binder, supplement, or medication will produce lasting improvement if you continue living or working in a water-damaged building [2].

Options:

• Professional remediation: Hire a certified mold remediation company (IICRC-certified). Ensure they follow containment protocols. Post-remediation testing (ERMI or HERTSMI-2) should confirm success.
• Temporary relocation: If remediation will take weeks to months, consider staying elsewhere. Many patients report symptom improvement within 1-2 weeks of leaving the contaminated environment.
• Moving: In cases of severe structural damage, moving may be more practical and cost-effective than remediation.

Important: cross-contamination matters. Clothing, furniture, and personal belongings can carry mycotoxins and spores. Some patients need to clean or replace soft furnishings, and certain porous items may not be salvageable.

Step 2: Binding Agents

Once exposure is eliminated, the next step is accelerating biotoxin removal from the body. Biotoxins are excreted through bile into the GI tract, but they undergo enterohepatic recirculation, meaning they get reabsorbed from the intestines back into the bloodstream. Binders break this cycle by binding to biotoxins in the gut and carrying them out in stool [3].

Cholestyramine (CSM)

CSM is the most studied binder for CIRS. It’s a prescription bile acid sequestrant originally used for high cholesterol. In the CIRS context, it binds biotoxins in the gut with high affinity.

• Dose: Typically 4g (one packet), four times daily before meals
• Duration: 30 days minimum, often 2-3 months
• Side effects: Constipation (the most common), bloating, GI discomfort. Starting at a lower dose and titrating up reduces side effects.
• Drug interactions: CSM binds many medications and supplements. Take all other medications 1 hour before or 4 hours after CSM.

Response is monitored with VCS testing. Improvement in visual contrast scores typically occurs within 2-4 weeks of starting CSM in patients who have left the moldy environment.

Welchol (Colesevelam)

An alternative bile acid sequestrant that some patients tolerate better than CSM. It binds a similar range of biotoxins but causes less constipation. Available in tablet form, which is more convenient than CSM powder. It’s less studied in the CIRS-specific literature but used widely by CIRS-trained clinicians.

Activated Charcoal

A broad-spectrum binder that adsorbs mycotoxins and other toxins in the GI tract. Less targeted than CSM but more accessible (available over the counter). Typically used as an adjunct rather than a primary binder. Take 500-1000mg between meals, separated from medications and supplements.

Bentonite Clay

A natural clay binder with documented affinity for aflatoxins and ochratoxin A. Research in agricultural science shows strong mycotoxin binding capacity [4]. Clinical evidence in human CIRS treatment is limited, but mechanistically sound. Available as a supplement. Mix with water and take between meals.

Modified Citrus Pectin

Binds certain metals and toxins. Some CIRS practitioners include it in their binder rotation. Evidence is preliminary but it has a favorable safety profile and may support gut barrier repair simultaneously.

Step 3: Address MARCoNS

MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) is a deep nasal biofilm infection found in roughly 80% of CIRS patients. These bacteria are not pathogenic in the traditional sense, but they produce exotoxins that cleave MSH (melanocyte-stimulating hormone), perpetuating the inflammatory cycle [5].

Testing: Deep nasal culture (not a standard sinus swab). The API Staph test identifies the species and resistance pattern.

Treatment:

• BEG spray (Bactroban, EDTA, Gentamicin): A compounded nasal spray that penetrates the biofilm. Used 2-3 times daily for 30 days.
• Silver nasal spray: Colloidal silver nasal spray as an alternative or adjunct. Some practitioners use silver as first-line before BEG.
• Biofilm disruptors: NAC (N-acetylcysteine) and EDTA help break down the biofilm matrix.

MARCoNS often recurs if the patient returns to a moldy environment, which is why environmental remediation must come first.

Step 4: Correct Inflammatory Markers

With exposure removed, binders working, and MARCoNS addressed, attention turns to normalizing the inflammatory biomarkers that drive symptoms:

Anti-Gliadin Antibodies

Many CIRS patients develop elevated anti-gliadin antibodies (not celiac disease, but innate immune activation against gluten proteins). A gluten-free trial for 3-6 months is standard if these antibodies are elevated. Many patients find GI symptoms and brain fog improve significantly.

MMP-9 and TGF-beta 1

If these remain elevated after binder therapy:

• High-dose omega-3 fatty acids (EPA/DHA 2.4g/day): Reduces MMP-9 through anti-inflammatory pathways
• Low amylose diet: Reduces starch intake to lower TGF-beta 1. This means avoiding most grains, potatoes, and high-starch foods.
• Losartan: An angiotensin receptor blocker that directly inhibits TGF-beta 1 signaling. Used off-label in CIRS at low doses (25-50mg).

VEGF Correction

Low VEGF impairs oxygen delivery to tissues. Treatment includes high-dose omega-3s and, in refractory cases, erythropoietin (EPO) in very low doses under specialist supervision.

Step 5: VIP Nasal Spray

Vasoactive Intestinal Peptide (VIP) is the final step in the Shoemaker Protocol and only initiated after all preceding steps are completed. VIP is a regulatory neuropeptide that modulates inflammation, supports blood-brain barrier integrity, and regulates pulmonary artery pressure [6].

VIP is compounded as a nasal spray (50 mcg per spray, typically 4 sprays per day). Studies show it normalizes TGF-beta 1, C4a, and VEGF in patients who have completed the prior steps. Response rates drop significantly if VIP is started before MARCoNS eradication and binder therapy completion.

Supportive Therapies

These don’t replace the core protocol but support recovery:

• Glutathione support: Liposomal glutathione (500-1000mg/day) or NAC (600-1200mg/day) supports Phase II liver detoxification. Glutathione conjugation is a primary mycotoxin clearance pathway.
• Sauna therapy: Infrared sauna (20-40 minutes, 3-5 times per week) promotes mycotoxin excretion through sweat. Start slowly to avoid mobilizing toxins faster than the body can clear them.
• Probiotics: Multi-strain probiotics support gut barrier integrity and reduce enterohepatic recirculation of biotoxins. Saccharomyces boulardii has specific evidence for mycotoxin binding in the gut [7].
• Nasal irrigation: Xylitol-based nasal rinses help maintain sinus health post-MARCoNS treatment.

Recovery Timeline

Recovery from CIRS is not linear. Expect fluctuations. General timeframes:

Patients with multisusceptible HLA types (carrying two CIRS-associated haplotypes) typically take longer. Those who return to contaminated environments before completion relapse rapidly.

What Doesn’t Work

• Antifungal medications alone: CIRS is not a fungal infection. It’s an inflammatory response to biotoxins. Fluconazole and itraconazole don’t address the core pathophysiology.
• Generic “detox” protocols: Juice cleanses, liver flushes, and unstructured supplement regimens don’t provide the specific binding capacity needed to interrupt enterohepatic recirculation.
• Treating individual symptoms without the protocol: Taking an antidepressant for mood, an anti-inflammatory for pain, and an antihistamine for congestion treats downstream effects without addressing the upstream cause.
• Skipping environmental remediation: No treatment overcomes ongoing exposure. This is the most common reason for treatment failure.

Finding a CIRS-Trained Practitioner

CIRS treatment requires specific knowledge that most primary care doctors and even most specialists have not been trained in. Look for practitioners who:

• Are certified through the Shoemaker Protocol training program
• Order the full CIRS biomarker panel (not just standard blood work)
• Understand environmental testing (ERMI/HERTSMI-2)
• Follow the stepwise treatment sequence
• Monitor progress with VCS testing and biomarker tracking

Related Reading

• Mold Illness and CIRS: The Evidence-Based Guide (Pillar)
• Mold Illness Symptoms: How to Tell If Mold Is Making You Sick
• Leaky Gut Symptoms: Signs Your Gut Barrier Is Compromised
• IV Therapy Benefits and Risks: What the Evidence Says

References

1. Shoemaker RC, House D, Ryan JC. Structural brain abnormalities in patients with inflammatory illness acquired following exposure to water-damaged buildings. Neurotoxicol Teratol. 2014;45:18-26. doi:10.1016/j.ntt.2014.06.004
2. Mudarri D, Fisk WJ. Public health and economic impact of dampness and mold. Indoor Air. 2007;17(3):226-235. doi:10.1111/j.1600-0668.2007.00474.x
3. Shoemaker RC, Hudnell HK, House DE, et al. Atovaquone plus cholestyramine in patients seropositive for Babesia microti. Toxicol Ind Health. 2006;22(2):75-84.
4. Phillips TD, Sarr AB, Grant PG. Selective chemisorption and detoxification of aflatoxins by phyllosilicate clay. Nat Toxins. 1995;3(4):204-213. doi:10.1002/nt.2620030407
5. Brewer JH, Thrasher JD, Straus DC, et al. Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins (Basel). 2013;5(4):605-617. doi:10.3390/toxins5040605
6. Shoemaker RC, Ryan JC, Mark L. VIP response in patients with chronic inflammatory response syndrome following exposure to water-damaged buildings. Internal Medicine Review. 2017;3(5):1-17.
7. Yiannikouris A, Andre G, Poughon L, et al. Chemical and conformational study of the interactions involved in mycotoxin complexation with beta-D-glucans. Biomacromolecules. 2006;7(4):1147-1155. doi:10.1021/bm050968t
8. Hope J. A review of the mechanism of injury and treatment approaches for illness resulting from exposure to water-damaged buildings, mold, and mycotoxins. ScientificWorldJournal. 2013;2013:767482. doi:10.1155/2013/767482